Swedish Life Sciences Stock News

OM:EVO
OM:EVOHospitality

Assessing Evolution (OM:EVO) Valuation After Weaker Q4 And Full Year 2025 Earnings

Why Evolution’s latest earnings matter for shareholders Evolution (OM:EVO) has come under closer scrutiny after reporting its fourth quarter and full year 2025 results, with both revenue and net income lower than the prior year. This has prompted fresh questions about the stock’s recent slide. See our latest analysis for Evolution. The share price has retreated to SEK523.6, with a 1-day share price decline of 2.42% and a year-to-date share price decline of 16.12%, while the 1-year total...
OM:CLAS B
OM:CLAS BSpecialty Retail

Assessing Clas Ohlson (OM:CLAS B) Valuation After Strong Organic Sales Growth Update

Sales update and why it matters for Clas Ohlson (OM:CLAS B) Clas Ohlson (OM:CLAS B) just released its January 2026 sales update, reporting SEK 1,005 million for the month and SEK 9,903 million year to date, with 7% growth driven entirely by 9% organic expansion. See our latest analysis for Clas Ohlson. The January sales update comes as Clas Ohlson’s share price has gained 6.26% over the past week and 17.38% over the past month, with a 1 year total shareholder return of 42.36%, suggesting...
OM:VITR
OM:VITRBiotechs

Vitrolife (OM:VITR) Valuation After Fourth Quarter Loss And Sharp Full Year Setback

Vitrolife (OM:VITR) is back in focus after reporting fourth quarter and full year 2025 results, with sales of SEK 891 million for the quarter and a net loss of SEK 5,314 million. See our latest analysis for Vitrolife. Despite a 4.36% 1 day share price gain to SEK89.7 after the earnings release, Vitrolife’s 30 day share price return of 32.61% and 1 year total shareholder return of 56.22% indicate pressure has been building for some time as investors reassess the business after the large...
OM:MCOV B
OM:MCOV BHealthcare

Medicover (OM:MCOV B) Valuation Check After Full Year 2025 Earnings And Profit Growth

Medicover (OM:MCOV B) is back in focus after reporting fourth quarter and full year 2025 results, with higher sales and net income from continuing operations compared with the previous year. See our latest analysis for Medicover. The earnings release has drawn fresh attention to Medicover, with the share price at SEK209.0 and recent trading showing mixed momentum, including a 7 day share price return of 2.70% and a 90 day share price return of 11.25%. The 5 year total shareholder return of...
OM:ALLIGO B
OM:ALLIGO BTrade Distributors

Alligo (OM:ALLIGO B) Margin Compression Challenges Bullish Narratives Despite Q3 EPS Of 1.64 SEK

Alligo (OM:ALLIGO B) has put fresh numbers on the table for FY 2025, with third quarter revenue of SEK 2,189 million, EPS of 1.64 SEK and net income of SEK 82 million, against a share price sitting around SEK 135. The company has seen quarterly revenue move between SEK 2,143 million and SEK 2,612 million over the last six reported periods, while EPS has ranged from 0.34 SEK to 2.12 SEK. This gives investors a view of how earnings track against a trailing net margin of 2.6% compared with 3.8%...
OM:VSURE
OM:VSURECommercial Services

Assessing Verisure (OM:VSURE) Valuation After Q4 2025 Sales Growth And Wider Net Losses

Balancing higher sales and wider losses Verisure (OM:VSURE) has drawn fresh attention after reporting Q4 and full year 2025 results, with sales of €964.7 million in the quarter and €3.7b for the year alongside wider net losses. That mix of higher revenue and larger losses gives you a lot to weigh up, especially given the stock’s recent negative returns over the month and past 3 months. Here is how those headline figures fit together. See our latest analysis for Verisure. Verisure’s latest...